SCHEMBL7850856

SCHEMBL7850856

O=S(=O)(OCl)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
CYP3A4 P08684 1/20 0.56
MAPK1 P28482 1/20 0.56
CA1 P00915 5/20 0.52
CA2 P00918 5/20 0.52
CA9 Q16790 4/20 0.52
CA12 O43570 3/20 0.52
CA3 P07451 3/20 0.52
CA4 P22748 3/20 0.52
CA6 P23280 3/20 0.52
CA5A P35218 3/20 0.52
CA7 P43166 3/20 0.52
CA13 Q8N1Q1 3/20 0.52
CA14 Q9ULX7 3/20 0.52
CA5B Q9Y2D0 3/20 0.52
TDP1 Q9NUW8 1/20 0.50
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1969965 0.82 ALDH1A1 (0.59) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL28864044 0.82 ALDH1A1 (0.59) ALDH1A1CYP3A4MAPK1CA1CA2
Water SCHEMBL11132230 0.80 CA12 (0.44) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL28049658 0.79 MAPT (0.53) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL28864047 0.78 ALDH1A1 (0.54) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL1985748 0.78 ALDH1A1 (0.54) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL27591962 0.78 MEN1 (0.47) ALDH1A1CA1CA2KMT2AMEN1
SCHEMBL197599 0.78 ALDH1A1 (0.54) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL17278786 0.78 CA2 (0.50) ALDH1A1CA1CA2CA9CA12
SCHEMBL2535039 0.78 GAA (0.54) ALDH1A1CYP3A4MAPK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093695-A1 Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors SCHERING CORP. 2010-04-15 US disclosed
EP-0605729-B1 OXAZOLIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2000-07-26 EP disclosed
US-5480899-A ANTILIPEMIC AGENTS TAIHO PHARMACEUTICAL CO., LTD. (JP) 1996-01-02 US disclosed
EP-0605729-A1 OXAZOLIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1994-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093695-A1 Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors BACE1, BACE2, APP ALDH1A1 3632/4885CYP3A4 1147/4885MAPK1 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.